Abstract
Introduction
The renin-angiotensin-aldosterone system (RAAS) plays a major role in defense of extracellular fluid volume and cardiovascular function. AngII induces sodium retention; decrease renal blood flow and GFR, general systemic vasoconstriction, secretion of aldosterone from the adrenal cortex, and possibly release of vasopressin from the pituitary gland (35) . These classical actions have been ascribed to AngII acting through AT 1 receptors (2, 43) . AT 2 receptors may mediate functions opposite of those mediated by the AT 1 receptors (14) . A decrease in plasma AngII concentration is an essential element in the immediate natriuretic response to modest volume loading in conscious dogs (6, 39) .
However, available data on the renal actions of angiotensin fragments imply a more complex role of the RAAS (3). AngII may not be the only biologically active peptide, and fragments of AngII may mediate some of the effects previously attributed to AngII. Firstly, studies of the actions of AngIII (des-Asp 1 -angiotensin II) in the rat (32, 29) and in anaesthetized dogs (24, 11) indicate that infusion of AngIII might produce vasoconstriction, sodium retention, aldosterone release. This response is thought to be similar to AngII although not as potent. Secondly, the discovery of several putative receptors for various angiotensin peptides has generated interest in the actions of other peptides produced in vivo from AngI, such as AngIV (des-Asp 1 -Arg 2 -Angiotensin II) and Ang(1-7) (des-Phe 8 -Angiotensin II). Recently, a novel AT 4 -receptor with high affinity towards AngIV has been described in the rat kidney (27) . Very little is known about the renal actions of AngIV; so far the AT 4 -receptor seems mainly to be considered a neuroendocrine receptor (45) , and although the AT 4 -receptor has been found in the kidney, AngIV mediated renal effects remain obscure (27) . Kohara et al. and Fer- rario et al. (34, 22) showed that Ang(1-7) is a biologically active circulating metabolite of the angiotensin peptide family, formed through pathways independent of converting enzyme, and that it possesses biological activity distinct from AngII and AngIII. The data of DelliPizzi et al. (17) supported the hypothesis demonstrating a natriuretic response to Ang (1) (2) (3) (4) (5) (6) (7) in the isolated rat kidney. Subsequently, several groups have shown an anti-diuretic and anti-natriuretic effect of Ang(1-7) (30, 23) , although in large doses given to anesthetized animals. Ang(1-7) has also been shown to increase GFR, urine flow, and electrolyte excretion through production of prostaglandin I 2 (31) .
Thirdly, characterization of the turn-over rate of the various angiotensin peptides has been attempted in the conscious sheep model (11,21), but not during blockade of the endogenous RAAS.
The present experiments were designed to study the metabolic clearance rate for the angiotensin fragments and to test the hypothesis that infusion of fragments of angiotensins, i.e. AngIII, AngIV and Ang(1-7) during constant low RAAS activity, exert biological effects, e.g. in blood pressure, and in renal excretion rates of electrolytes and water, when infused into conscious dogs in amounts which can be considered physiological. Prior to the infusion of the angiotensin peptides, the RAAS was blocked acutely. This is a key feature of the present investigation. It is a substantial advantage to limit the endogenous peptide synthesis so that changes in endogenous production does not obscure the true effect of the infused peptides. Without ACE inhibition, it would be impossible to determine the relative contribution of endogenous and exogenous peptide. Infused angiotensin would to an unknown extent replace a decrease in endogenous production induced by the elevated plasma peptide concentration. Further, when studying the acute renal effects of angiotensin peptides, the effects of aldosterone should be inhibited to provide the best platform for observation of the specific peptide effects. This is, to our knowledge, the first study to use this approach when studying both turnover and physiological effects of different angiotensin peptides.
Methods
Animals. Experiments were performed in six female conscious Beagle dogs weighing 12. At 1000 h (t = 0 min) the experiment was initiated. Following a 30 min control period, infusion of vehicle or synthetic peptide (AngII, AngIII, AngIV or Ang(1-7)) was initiated and continued for 120
min. The infusion of peptide was followed by a 30 min recovery period. The time line of the experiments is shown in Figure 1 .
Throughout the three-hour experiment urine was collected every 30 min. At the end of each period the bladder was flushed 3 times with distilled water carefully avoiding air in the drainage system.
Urine samples were obtained for the determination of osmolality, sodium, potassium, and creatinine.
Small samples of arterial blood were obtained at the beginning of the experiment and at the end of each sampling period for determination of plasma creatinine. Larger samples (≈17 ml) were collected at t = 25, 85, 145, and 175 minutes for analyses of electrolyte, protein, and hormone concentrations (see Figure 1 ).
All peptides were purchased from Peninsula Laboratories Europe, UK. Each peptide was first dissolved in aqueous acetic acid (0.25% adjusted to pH = 4.5) to a 10 nmol/ml stock solution stored at -18°C. The stock solution was further diluted in a hypotonic solution of glucose and urea to a 600 pmol/ml working solution immediately prior to infusion.
In all series, peptides were administered at a rate of 6.0 pmol/kg/min, except (i) in additional separate experiments where AngIII was infused at 30 pmol/kg/min for one hour and then at 150 pmol/kg/min in the subsequent hour and (ii) in time control experiments where only vehicle was infused.
Hemodynamics. A pressure transducer (BLPR, World Precision Instrument, Hertfordshire, UK) measured the arterial blood pressure continuously. The signal was amplified (pre-amplifier, PB1-C, World Precision Instruments, Hertfordshire, UK) and digitized by a computer at a frequency of 100
Hz using a standard IO-card (National Instruments, Austin, TX) and custom designed software (Lab View, National Instruments). Beat-to-beat systolic, diastolic and mean pressures and heart rate were determined from the pressure curve. Data were stored on disc and averaged over 30-min periods. Plasma hormones. Arterial blood samples for hormone analysis were obtained in prechilled 10 ml polyethylene tubes (Minisorb, Nunc, Denmark) containing EDTA (25 µmol) and aprotinine (NovoNordisk, Bagsvaerd, Denmark) The samples were centrifuged at 4° C for 10 min and then stored at -18° C until extraction. Hormone extraction was performed according to the method described by
Plovsing et al. (38) .
Vasopressin. Plasma vasopressin was measured using an antibody (AB3096) produced in this laboratory and using the methods described by Emmeluth et al. (19) . Detection limit was 0.16 pg/ml of plasma and mean recovery of unlabelled vasopressin was close to 70%. Intra-and interassay coefficients were 4.9% and 7.3% respectively.
AngIR. The plasma angiotensin immunoreactivity was measured in extracts of plasma using an antibody (Ab-5-030682). Separate measurements demonstrated 100% crossreactivity of AngIII and
AngIV, but the antibody does not recognize either AngI or Ang(1-7) (cross reactivity <10 -4 ). Detection limit was 1.0 pg/ml of plasma and mean recoveries of unlabeled peptide added to dog plasma for AngII, AngIII and AngIV were 91%, 76% and 93%, respectively. Assuming stable concentrations in plasma of endogenous peptides during peptide infusion, the increase in AngIR can be used to determine metabolic clearance rates of the various peptides. For these calculations all values were corrected for incomplete recovery determined in each individual assay.
by a one-way ANOVA for repeated measurements between and within groups. If the results of the ANOVA were significant (P < 0.05) all differences were investigated by Newman-Keuls test. P < 0.05 were considered statistical significant.
Results
AngIR. During time control experiments, plasma angiotensin immunoreactivity was low and constant at about 5 pmol/l (baseline, figure 2 ). The infusion of AngII raised AngIR by 60 pmol/l. This elevation was stable throughout the infusion and corresponds to a metabolic clearance rate of AngII of about 100 ml/kg/min ( Table 1) . Administration of equimolar amounts of AngIII generated increases in AngIR much smaller than those of AngII. In addition, infusion of AngIII did not produce a steady-state situation as seen in the AngII series. The AngIII infusion raised AngIR to about 30 pmol/l above baseline after one hour of infusion, but it declined significantly to about 15 pmol/l in the subsequent hour despite the ongoing constant infusion. Despite the lack of a steady-state situation clearance values were calculated at the end of both the first and the second hour of infusion. These values must be regarded as minimal clearance rates. The AngIV infusion produced a constant elevation similar to that of the second hour of AngIII infusion so that mean AngIR was 16 pmol/l throughout the AngIV infusion.
Metabolic clearance rate. Calculated for each hour of infusion, the clearances of AngII were similar ( Table 1 ). The clearances of AngIII and AngIV were significantly higher (by factors 2 and 4, see Table 1 ). The clearance for AngIII was not significantly different from the clearance of AngII in the first calculation period, but the subsequent increase in AngIII clearance was highly significant.
The clearance rates of AngIV were similar in the two calculation periods. In the experiments with infusion of larger amounts of AngIII, the metabolic clearance rate declined in the second period.
Cardiovascular variables. After ACE-inhibition mean arterial blood pressure (MABP) was about 97 mmHg (Table 2) . With AngII infusion it increased to about 120 mmHg returning gradually to the pre-infusion level in the recovery period, for which the 30-min mean was 106 mmHg. At the end of the experiments blood pressure was to pre-infusion level. Heart rate remained unchanged.
AngIII (6 pmol/kg/min) produced a tendency towards an increase in blood pressure (96 to 106 mmHg, p≈0.055). With the larger doses of AngIII the dogs became markedly hypertensive. At 30 pmol/kg/min blood pressure rose almost instantly to a mean of 123 mmHg, i.e. very similar to that generated by AngII at 6 pmol/kg/min. A further increase was observed when the infusion rate was increased to 150 pmol/kg/min; in the first 30-min period a mean value of 140 mmHg was obtained, reflecting a gradual increase in this period to the blood pressure of about 153 mmHg, which remained stable in the last 30-min infusion period (Table 2 ). In the recovery period, blood pressure returned almost immediately to its control value (101 mmHg). AngIV and Ang(1-7) did not cause significant changes in blood pressure. Low and constant control values of heart rate, around 70 beats per min, were observed in all series. Heart rate changed significantly, but modestly, in individual periods of some of the series; however, the changes appeared apparently unrelated to infusions.
Plasma variables.
Only minor changes were observed in plasma osmolality, plasma protein, plasma sodium, and plasma potassium (Table 3) .
Vasopressin. Although plasma osmolality tended to decline throughout the experiments, the plasma vasopressin concentration almost doubled (+88%) upon infusion of AngII (Table 3) . However, this plasma level was not sustained throughout the 2-hour infusion period despite a constant high AngIR. In the Ang(1-7) series the plasma concentration of vasopressin was low and constant, as in the time control series. Within the AngIV series, the plasma vasopressin level increased modestly,
but to values lower than in time control experiments. In contrast, the larger dose of AngIII stimulated vasopressin release dose dependently.
Aldosterone. In the time control series plasma aldosterone was declining throughout the experiment (Table 3) . Infusion of AngII and AngIII stimulated aldosterone release similarly (plasma concentration rose to 345±72 pg/ml and 268±71 pg/ml, respectively). Surprisingly, the high dose of 30 pmol/kg/min AngIII did not increase plasma aldosterone more than infusion of 6 pmol/kg/min. Fur-ther elevation of the AngIII dose to 150 pmol/kg/min did indeed increase aldosterone concentration to about 550 pg/ml. Neither AngIV nor Ang(1-7) raised plasma aldosterone concentration. In contrast, declines similar to time control experiments were observed in both cases.
Atrial Natriuretic Peptide (ANP). The ANP concentration also declined steadily through the time control series. During infusion of both AngII and AngIII, the plasma ANP concentration increased without a concomitant increase in the sodium excretion. In the AngIV and Ang(1-7) series, the plasma ANP concentration declined in a manner very similar to time control experiments.
Renal variables
AngII. AngII markedly reduced GFR, which decreased by some 18% with the onset of peptide infusion (Table 4) . Urine flow immediately decreased to about one third of pre-infusion value, as did sodium excretion. However, in the recovery period the sodium excretion continued to be low, at about 20% of pre-infusion value, and surprisingly no rebound effect was observed. Urine osmolality increased during AngII infusion (Table 4) .
AngIII. AngIII at the standard dose of 6 pmol/kg/min did not affect GFR significantly, although a tendency towards a reduction was seen. A significant decrease in GFR was produced (from 38 to 27 ml/min) by the higher AngIII dose of 30 pmol/kg/min ( Table 4 AngIV and Ang(1-7) series. GFR did not change upon infusion of either of these peptides. Mean sodium excretion and urine flow were not significantly different from time control levels in either series.
Time control series. All renal variables remained stable throughout the time control series.
Discussion
The purpose of this study was to test the hypothesis that infusion of angiotensin peptides in low physiological doses, under conditions of low and constant endogenous RAAS-activity, would produce measurable changes in renal and cardiovascular parameters, and to characterize the turnover rate of the peptides. The present results support the notion of physiological effects of AngIII, perhaps through yet unidentified mechanisms, but cannot support the hypothesis that AngIV or Ang(1-7) induces changes in blood pressure and renal sodium excretion.
The pre-treatment was performed acutely before each experiment in order to avoid any significant changes in body fluid status, and the applied regime was very effective in producing stabile natriuresis and diuresis (Table 4 and Figure 3) Our data show very clearly that both AngIII and AngIV are metabolized much faster than AngII (see Table 1 ), although the AngIII turn over was not calculated from steady state values, they represent the minimal clearance rates of AngIII. The true clearance rate may be much higher than these calculated values. The differences mentioned above between the present results and the data obtained by Fei et al. (21) and Britton et al. (11) might be attributable to differences in experimental design. In our study the endogenous RAAS was inhibited pharmacologically in contrast to the other two studies.
Our data, therefore, are not influenced by possible changes in endogenous generation rate of AngII during infusion of the peptide. In addition, the calculations of Fei et al. (21) are based on arteriovenous measurements whereas our calculations are based on continuous infusions to a steady state level of peptide. Further, a substantially larger clearance of AngIII compared to AngII is compatible with the rapid return of renal and cardiovascular variables towards control level, which was seen in the recovery period. AngIII infusions (both 6 and 150 pmol/kg/min) showed a remarkable rapid offeffect compared to AngII; after infusion of the latter, GFR, urine flow and sodium excretion showed no sign of rebound in the recovery period despite the finding that the AngIR in plasma returned to preinfusion level. Our results demonstrate that it is essential to measure plasma concentrations of the various peptides in order to evaluate their potency. Due to marked differences in plasma clearance of the peptides it is invalid to assume that similar plasma concentrations are generated by equimolar infusion rates.
Larger clearance rates of AngIII and AngIV compared to AngII were also found in investigations performed on healthy humans in our laboratory (38) , where infusion of AngIII elicited substantial effects on aldosterone secretion and renal function at doses too low to generate measurable increases in AngIR.
The observed effects of the AngII infusion were expected (20, 26) . AngIR showed a steady state of about 65 pmol/l and this led to a decrease in sodium excretion, GFR, urine flow and an increase in MABP and urine osmolality. Heart rate and plasma electrolyte, osmolality, and protein concentration were unaffected by peptide infusion. Constancy of heart rate is a well know phenomenon during AngII mediated changes in blood pressure (8) . Usually the actions of AngII are immediate and related to the plasma concentration of the peptide. Therefore, it is puzzling that sodium excretion, GFR, and urine volume remained depressed in the recovery period under conditions where AngIR, and blood pressure had returned almost to pre-infusion level.
The effects of AngIII were surprising in the sense that a much lower plasma concentration was needed to produce a very potent anti-natriuretic response immediately after the onset of the infusion compared to AngII. The anti-natriuretic effect was observed without changes in blood pressure, vasopressin, or GFR. This supports the findings made by Huang (32) , who reported that AngIII produced anti-natriuresis without an increase in blood pressure. However, the present finding of high potency of AngIII over that of AngII has not been reported previously. Further, the increase in blood pressure produced by AngII does not lead to pressure natriuresis, because a concomitant reduction in GFR is observed. Therefore pressure natriuresis cannot explain that relative to AngII a much lower plasma concentration of AngIII was needed to produce the same reduction in sodium excretion. Freeman et al. (24) showed a tendency towards a reduction in sodium excretion in anesthetized dogs upon AngIII infusion at 25 ng/kg/min (corresponding to 23 pmol/kg/min) without significant changes in GFR or MABP. Using approximately the same dose of AngIII (30 pmol/kg/min), we find a more potent response in our experiments; including a 27% reduction in GFR (37±2 to 27±2 ml/min) along with an 85-90% decrease in sodium excretion (57±8 to 7±1 mol/min) and urine flow (0.9±0.3 to 0.1±0.0 ml/min). This clearly demonstrates that when the plasma concentration of AngIII is brought to a level comparable to that of AngII, the effects of AngIII are in some respects quite similar (GFR, increases in Uosm, pAVP, pAldo), in others markedly exaggerated (Na + , K + retention). We observed that at similar levels of AngIR, the blood pressure elevations generated by AngII and AngIII were identical (to 121±4 and 123±3 mmHg, respectively). This supports the notion that AngII and AngIII bind to the same receptors in the vasculature with similar affinities, probably to the AT 1 receptor, as reported by Chiu et al. (15) . However, the anti-natriuretic response to AngIII infusion may in fact be mediated through a mechanism entirely different from that activated by AngII.
Several groups have shown previously that AngIII stimulates aldosterone secretion in a manner similar to AngII (9, 36); however, the relative contribution of the peptides to aldosterone release has When two peptides are compared on the basis of identical infusion rates, the plasma clearances must be assumed to be equal in order to interpret the data in a useful manner. In the present study, we demonstrate that AngIII is significantly more potent than AngII with regard to aldosterone release, when estimated on the basis of plasma concentrations of AngII and AngIII (Table 3 ). This is also true in healthy humans (38) , where AngIII increases plasma aldosterone concentrations upon AngIII infusion at such a low rate, that plasma AngIII does not rise measurable. In the present study, aldosterone release was remarkably sensitive to small amounts of AngIII, but surprisingly insensitive to increases in plasma AngIII concentration as identical aldosterone responses were observed during both 6 and 30 pmol/kg/min infusion rates. Semple and co-workers (42) demonstrated higher potency of AngII compared to AngIII in eliciting an increase in plasma aldosterone concentration. Further, AngIII may not be essential to the aldosterone release mechanism; Douglas et al. (18) showed that AngII is a potent stimulator of aldosterone without prior conversion to the heptapeptide. These observations do not correspond to our findings. However, differences between experimental protocols, e.g., endogenous RAAS blockade, may again be the reason. We find a non-linear relation between plasma AngIII concentration and aldosterone release, which might be explained by operation of two receptor mechanisms, one with a high affinity and low capacity possibly triggered only by AngIII, and another with a lower affinity, but a larger maximal response.
Ang(1-7) administered in a low dose did not change the measured renal and cardiovascular variables. When ACE is inhibited, more substrate is available for the Ang(1-7) producing pathway. ACE is a key enzyme in the bradykinin turnover, consequently ACE-inhibition will increase the circulating bradykinin and nitric oxide formation. Effects of Ang(1-7) might be blunted by the ACE-inhibition, which is reported to increase the bradykinin concentration by a factor of eight, because Ang(1-7) is thought to work partly through an increase in bradykinin concentration due to competition for ACE (46, 12) . Other investigators (30, 23, 27) have shown both diuretic and natriuretic effects of circulating Ang(1-7), but in doses much greater than used in the present study.
In the present setting, absence of an effect is not particularly informative. Especially AngIV and Ang(1-7) may play important local and paracrine roles in the organism and may even be important as classical hormones in amounts larger than those studied here.
Perspectives
The present study provides further evidence that the effect of the RAAS is more complex than previously believed. AngIII seems to be a more important mediator of aldosterone secretion and sodium excretion than previously thought. Our results include patterns of effects, which are very difficult to explain based on known receptor systems. Therefore, they provide evidence, albeit indirect, that all types of receptors sensitive to angiotensin peptides might not yet have been identified. It would be interesting to elucidate the exact mechanism, by which AngIII is working. The present investigation was not designed to do so. Nevertheless, it is tempting to suggest that a plausible explanation of our data require a very sensitive and specific AngIII receptor in addition to AngIII actions elicited via AngII receptors. Should a pathway different from the well-known AngII receptor pathways be found to mediate some of the effects of AngIII particularly at low concentrations, it could be an important element in the normal physiological homeostasis as well as in the pathophysiology of major diseases, e.g. hyperaldosteronism and essential hypertension. Values are expressed as mean ± SE (n = 6) Angiotensin peptides were infused from t = 30 min to t = 150 min. (In the AngIII High dose series infusion was 30 pmol/kg/min from t = 30 min to t = 90 min and at 150 pmol/kg/min from t = 90 min to t = 150 min); *significantly different from preinfusion value (P < 0.05). †significantly different from time control series (P < 0.05) 
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